0.05Open0.05Pre Close0 Volume263 Open Interest0.50Strike Price0.00Turnover286.05%IV45.59%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1346Delta0.4052Gamma16.54Leverage Ratio-0.0031Theta-0.0001Rho-2.23Eff Leverage0.0004Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet